Abstract:Idiopathic pulmonary fibrosis (IPF) is a severe and currently incurable disease that is associated with irreversible fibrotic remodeling of the lung parenchyma. Pathological remodeling of the lung leads to damage of the alveolo-capillary barrier. There is a reduction in the diffusing capacity of the lungs for respiratory gases. Later, changes in the mechanical properties of lung tissue occur - their compliance decreases and respiratory work increases. Impaired respiratory gases exchange with restrictive ventilatory failure lead to tissue hypoxia and muscle weakness. Progressive respiratory insufficiency develops. The triggers of fibrotic remodeling of the lung are currently unknown, as are the pathomechanisms that keep this process active. IPF can only be slowed pharmacologically, not reversed. It is therefore very important to start its treatment as soon as possible. Early detection of IPF patients requires a multidisciplinary approach. Diagnosis, treatment initiation, and monitoring in specialized centers offer the best chance of slowing disease progression, enhancing quality of life, and extending patient survival. In addition to antifibrotic therapy, good lifestyle management, maintenance of physical fitness and treatment of associated chronic diseases such as diabetes and cardiac comorbidities are important. Lung transplantation is an option for some patients with IPF. This is a challenging treatment modality, requiring close collaboration with transplant centers and expert selection of suitable candidates, influenced, among other things, by the availability of suitable donor lungs. Our article aims to provide current information about IPF, focusing on its functional consequences and clinical manifestation. We discuss the molecular and cellular mechanisms potentially involved in IPF development, as well as the morphological changes observed in lung biopsies and high-resolution computed tomography (HRCT) images. Finally, we summarize the existing treatment options. Key words: Idiopathic pulmonary fibrosis, Lung biopsy, HRCT, Antifibrotic therapy, Lung transplantation.

Decoding the role of fatty acids and their metabolites in lung fibrosis

The Potentially Therapeutic Role of EPAC in Curbing the Process of Idiopathic Pulmonary Fibrosis Via Differential Cellular Pathways

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

Fatty Acid Metabolism and Idiopathic Pulmonary Fibrosis

Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy

Lipids - two sides of the same coin in lung fibrosis

Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis

Reexamining the Role of Pulmonary Lipids in the Pathogenesis of Pulmonary Fibrosis

Cellular and Molecular Control of Lipid Metabolism in Idiopathic Pulmonary Fibrosis: Clinical Application of the Lysophosphatidic Acid Pathway

Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies

Effect of lipid saturation and oxidation on fibrogenesis in IPF

Idiopathic Pulmonary Fibrosis: Review of Current Knowledge

The novel molecular mechanism of pulmonary fibrosis: insight into lipid metabolism from reanalysis of single-cell RNA-seq databases

Potential targeted therapy based on deep insight into the relationship between the pulmonary microbiota and immune regulation in lung fibrosis

High-Fat Diet Related Lung Fibrosis-Epigenetic Regulation Matters

[Lipid metabolism in idiopathic pulmonary fibrosis]

Role of Immune Cells in the Initiation and Progression of Pulmonary Fibrosis

Pulmonary fibrosis: pathogenesis and therapeutic strategies

Evidence from recent clinical trials in fibrotic interstitial lung diseases

Stearic acid attenuates profibrotic signalling in idiopathic pulmonary fibrosis